| RS2522919648 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522921855 |
UROD
|
Health Risk |
Likely pathogenic |
Familial porphyria cutanea tarda, Familial porphyria cutanea tarda |
| RS2522922098 |
UROD
|
Health Risk |
Likely pathogenic |
Familial porphyria cutanea tarda, Familial porphyria cutanea tarda |
| RS2522923201 |
UROD
|
Health Risk |
Pathogenic |
UROD-related disorder, UROD-related disorder |
| RS2522923651 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522924351 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522924439 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522925157 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522925387 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder |
| RS2522925422 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522927425 |
UROD
|
Health Risk |
Pathogenic |
UROD-related disorder, UROD-related disorder |
| RS2522927850 |
SPEN
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2522936231 |
MECR
|
Health Risk |
Pathogenic |
— |
| RS2522936339 |
SPEN
|
Health Risk |
Likely pathogenic |
Radio-Tartaglia syndrome, Radio-Tartaglia syndrome |
| RS2522937677 |
TAFAZZIN
|
Health Risk |
Conflicting classifications of pathogenicity |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522941783 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522941824 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522941954 |
MTHFR
|
Health Risk |
Likely pathogenic |
Neural tube defects, folate-sensitive |
| RS2522942574 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522942894 |
MTHFR
|
Health Risk |
Likely pathogenic |
Neural tube defects, folate-sensitive |
| RS2522943706 |
MTHFR
|
Health Risk |
Likely pathogenic |
Homocystinuria due to methylene tetrahydrofolate reductase deficiency, Neural tube defects |
| RS2522952803 |
MFSD2A
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2522961067 |
MTHFR
|
Health Risk |
Pathogenic |
Homocystinuria due to methylene tetrahydrofolate reductase deficiency, Homocystinuria due to methylene tetrahydrofolate reductase deficiency |
| RS2522963905 |
DOCK7
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 23 |
| RS2522975919 |
INTS11
|
Health Risk |
Pathogenic |
Neurodevelopmental disorder with motor and language delay, ocular defects |
| RS2522976055 |
KDM6A
|
Health Risk |
Pathogenic |
Kabuki syndrome 2, Kabuki syndrome 2 |
| RS2522976500 |
MSN
|
Health Risk |
Likely pathogenic |
Ovarian serous cystadenocarcinoma, Ovarian serous cystadenocarcinoma |
| RS2522976660 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2522978414 |
MTHFR
|
Health Risk |
Likely pathogenic |
Neural tube defects, folate-sensitive |
| RS2522979442 |
KDM6A
|
Health Risk |
Pathogenic |
— |
| RS2522979795 |
MTHFR
|
Health Risk |
Pathogenic |
Homocystinuria due to methylene tetrahydrofolate reductase deficiency, Homocystinuria due to methylene tetrahydrofolate reductase deficiency |
| RS2522980498 |
MTHFR
|
Health Risk |
Likely pathogenic |
Neural tube defects, folate-sensitive |
| RS2522982178 |
KDM6A
|
Health Risk |
Likely pathogenic |
Kabuki syndrome 2, Kabuki syndrome 2 |
| RS2522982515 |
MTHFR
|
Health Risk |
Pathogenic |
Homocystinuria due to methylene tetrahydrofolate reductase deficiency, Homocystinuria due to methylene tetrahydrofolate reductase deficiency |
| RS2522983092 |
KDM6A
|
Health Risk |
Pathogenic |
Kabuki syndrome 2, Kabuki syndrome 2 |
| RS2522984875 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2522984951 |
TAFAZZIN
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2522985080 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522985246 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522985442 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522985522 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522985614 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522986801 |
TAFAZZIN
|
Health Risk |
Conflicting classifications of pathogenicity |
3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder |
| RS2522987020 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522987117 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522990255 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522990298 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522990355 |
MTOR
|
Health Risk |
Pathogenic |
— |
| RS2522990592 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522995793 |
MTOR
|
Health Risk |
Likely pathogenic |
Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome, Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome |
| RS2522996339 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522996355 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522999559 |
TAFAZZIN
|
Health Risk |
Pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2523004237 |
CAMTA1
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2523004547 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2523006102 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2523006110 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2523010293 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523010703 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523010718 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523010895 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523016265 |
ATP6AP1
|
Health Risk |
Pathogenic |
Immunodeficiency 47, Immunodeficiency 47 |
| RS2523016325 |
ATP6AP1
|
Health Risk |
Likely pathogenic |
Immunodeficiency 47, Immunodeficiency 47 |
| RS2523017845 |
ATP6AP1
|
Health Risk |
Likely pathogenic |
Immunodeficiency 47, Immunodeficiency 47 |
| RS2523018241 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2523021283 |
MSN
|
Health Risk |
Pathogenic |
— |
| RS2523021639 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523030418 |
GDI1
|
Health Risk |
Likely pathogenic |
Intellectual disability, X-linked 41 |
| RS2523033056 |
GDI1
|
Health Risk |
Pathogenic |
Intellectual disability, X-linked 41 |
| RS2523035483 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2A2, Charcot-Marie-Tooth disease type 2A2 |
| RS2523036866 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2A2, Charcot-Marie-Tooth disease type 2A2 |
| RS2523037228 |
MFN2
|
Health Risk |
Likely pathogenic |
Auditory neuropathy, Auditory neuropathy |
| RS2523037323 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523037515 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523040871 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2523041143 |
DMD
|
Health Risk |
Likely pathogenic |
Becker muscular dystrophy, Becker muscular dystrophy |
| RS2523041411 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2523042495 |
DMD
|
Health Risk |
Likely pathogenic |
— |
| RS2523042827 |
FAM50A
|
Health Risk |
Conflicting classifications of pathogenicity |
Armfield syndrome, Armfield syndrome |
| RS2523043513 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2523043841 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2523043957 |
FAM50A
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2523045606 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Becker muscular dystrophy |
| RS2523048155 |
MACF1
|
Health Risk |
Likely pathogenic |
Lissencephaly 9 with complex brainstem malformation, Lissencephaly 9 with complex brainstem malformation |
| RS2523049776 |
ATP13A2
|
Health Risk |
Pathogenic |
Autosomal recessive spastic paraplegia type 78, Kufor-Rakeb syndrome |
| RS2523055286 |
ATP13A2
|
Health Risk |
Pathogenic |
Kufor-Rakeb syndrome, Kufor-Rakeb syndrome |
| RS2523057920 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523061214 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2523064807 |
BSND
|
Health Risk |
Pathogenic |
— |
| RS2523069166 |
RHCE
|
Health Risk |
Pathogenic |
RH-NULL, AMORPH TYPE |
| RS2523071377 |
DOCK7
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 23 |
| RS2523072017 |
DRP2
|
Health Risk |
Conflicting classifications of pathogenicity |
DRP2-related disorder, DRP2-related disorder |
| RS2523072193 |
MFN2
|
Health Risk |
Likely pathogenic |
MFN2-related disorder, MFN2-related disorder |
| RS2523072296 |
SPEN
|
Health Risk |
Likely pathogenic |
SPEN-related disorder, SPEN-related disorder |
| RS2523072429 |
SPEN
|
Health Risk |
Likely pathogenic |
Radio-Tartaglia syndrome, Radio-Tartaglia syndrome |
| RS2523072505 |
SPEN
|
Health Risk |
Likely pathogenic |
Radio-Tartaglia syndrome, Radio-Tartaglia syndrome |
| RS2523073518 |
SPEN
|
Health Risk |
Likely pathogenic |
— |
| RS2523075382 |
SPEN
|
Health Risk |
Likely pathogenic |
SPEN-related disorder, SPEN-related disorder |
| RS2523076978 |
ATP13A2
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2523079307 |
BSND
|
Health Risk |
Likely pathogenic |
— |